Grace Dy, MD, from the Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
Grace Dy, MD, Associate Professor, Department of Medicine, Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
As the oncology community has learned over time, the idea that the therapeutic index of targeted therapies as a group is much better than cytotoxics may not be entirely true. Certain toxicities such as myelosuppression or hair loss may not be as common in patients treated with targeted therapies.
Targeted therapies have shown that they can affect multiple organs in the body as some drugs inhibit targets found in normal tissues. This causes an entire spectrum of side effects that are difficult to anticipate. Targeted therapies make treatment much more interesting and challenging for a medical oncologist, Dy says.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More